Tempus AI (TEM) Stock Crash: Short Selling Report Analysis

Tempus AI Stock Plunge

• 📉 Tempus AI stock plummeted over 19% in a single day, closing at $53.2, wiping out billions in market cap.
• 🚨 The sharp decline was triggered by a "strong sell" report from renowned short-seller Spruce Point Capital.

Core Business & AI Claims

• 🔬 Tempus AI is a Chicago-based health tech company led by CEO Eric Lefkofsky, specializing in precision medicine for cancer diagnosis and treatment.
• 🧬 Its main services include genetic analysis, data-driven clinical trial matching, and data platforms for hospitals and pharmaceutical companies.
• 💡 The company has heavily promoted its AI technology as a core competency, especially after its IPO, attracting significant investor interest.

Spruce Point's Key Allegations

• 📊 Minimal AI Revenue: The report claims only 2% of Tempus AI's 2024 revenue ($14 million out of $690 million) was genuinely AI-related, suggesting an overreliance on AI as a marketing tool.
• ⚠️ CEO's Troubled Past: Spruce Point highlighted CEO Eric Lefkofsky's involvement in previous companies with a history of accounting issues, stock crashes, and shareholder losses.
• 🧾 Questionable Billing Practices: Tempus AI is accused of frequently using CPT code 81479 for genetic tests, a code known for its loose regulation and potential for overbilling or unnecessary procedures.

Further Concerns & Market Impact

• 🔄 Allegations include "round-trip" transactions with a SoftBank joint venture, implying artificial revenue generation through fund cycling.
• 📉 The report also claims a weakening partnership with AstraZeneca and a slowdown in the core genomics and data business, impacting future growth.
• 📉 Spruce Point warns of a potential 50-60% further decline in Tempus AI's stock, indicating structural risks beyond short-term volatility.

Investor Outlook

• 🔍 Investors are urged to exercise caution and not solely rely on optimistic views, considering the company's intrinsic value and regulatory risks.
• ⏳ The market awaits an official response from Tempus AI, with future stock movements likely influenced by their statement, upcoming earnings, and any potential government investigations into billing.